tecfidera
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
August 20, 2020Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …
Biogen stock surges following patent victory over Mylan for Tecfidera
February 6, 2020Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera
Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …
Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
September 11, 2019Research and Development Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …
Biogen shells out $1.25bn to protect best-selling MS drug
January 18, 2017Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera
Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Pharma is boosting pipelines to avoid patent cliff
February 11, 2015Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …
FDA green lights Lemtrada for MS
November 17, 2014Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera
The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …
FDA approves Biogen’s long-acting MS drug
August 18, 2014Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera
Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …
Strong sales for Biogen Idec’s MS drug
October 29, 2013Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera
Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …
Aubagio approved in Europe
September 3, 2013Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera
Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …
US nod for Tecfidera
March 28, 2013Sales and Marketing Biogen, FDA, tecfidera
The FDA has given Biogen Idec’s oral multiple sclerosis treatment Tecfidera the green light. Earlier this week Tecfidera (dimethyl fumarate) …
